Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs XP Inc. Class A Common Stock (XP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs XP Inc. Class A Common Stock — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while XP Inc. Class A Common Stock trades at $30.35 (market cap $15.93B). The key difference: XP Inc. Class A Common Stock is far larger — about 3.1× Oruka Therapeutics Inc. Common Stock's market cap, and XP Inc. Class A Common Stock pays a 0.64% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and XP Inc. Class A Common Stock for 5 Days on average.
| ORKA | XP | |
|---|---|---|
Market Cap | $5.18B | $15.93B |
Volume | 490,798 | 10,243,374 |
Sector | Health | Financials |
52-Week High | $113.08 | $32.60 |
52-Week Low | $26.19 | $14.94 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $4.31B | $25.63B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XP Inc. trades at $31.38, down 3.74% today but remains near recent highs. The stock shows strong fundamental performance with 63.12% net income margin and 22.58% ROE, supported by consistent earnings beats in recent quarters. Technical indicators show mixed signals with bullish moving averages but overbought RSI readings. Analyst sentiment remains strongly positive with 80% buy ratings and price targets suggesting significant upside potential from current levels.
The outlook for XP remains favorable given its robust profitability metrics and growing revenue base, though investors should monitor competitive pressures and market volatility. The company's strong cash flow generation and institutional support provide stability, while technical overbought conditions suggest potential near-term consolidation before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About XP Inc. Class A Common Stock
XP Inc. provides investment products and financial services in Brazil. Its platform includes brokerage, investment funds, fixed-income products, banking, insurance, and retirement solutions.
Read more on XP →
